Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Cipla
AstraZeneca
US Army
Federal Trade Commission
Medtronic
Fuji
Merck
UBS
Express Scripts

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,278,961

« Back to Dashboard

Which drugs does patent 9,278,961 protect, and when does it expire?


Patent 9,278,961 protects ERIVEDGE and is included in one NDA.

This patent has thirty-nine patent family members in twenty-two countries.

Summary for Patent: 9,278,961

Title:Pyridyl inhibitors of hedgehog signalling
Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: ##STR00001## wherein A, X, Y R.sub.1, R.sub.2, R.sub.3, R.sub.4, m and n are as described herein.
Inventor(s): Gunzner; Janet L. (Berkeley, CA), Sutherlin; Daniel (South San Francisco, CA), Stanley; Mark S. (Pacifica, CA), Bao; Liang (San Mateo, CA), Castanedo; Georgette M. (Redwood City, CA), Lalonde; Rebecca L. (Berkeley, CA), Wang; Shumei (Foster City, CA), Reynolds; Mark E. (Millbrae, CA), Savage; Scott J. (Burlingame, CA), Malesky; Kimberly (San Francisco, CA), Dina; Michael S. (Daly City, CA), Koehler; Michael F. T. (Palo Alto, CA)
Assignee: GENENTECH, INC. (South San Francisco, CA) CURIS, INC. (Lexington, MA)
Application Number:12/960,609
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Genentech
ERIVEDGE
vismodegib
CAPSULE;ORAL203388-001Jan 30, 2012RXYesYes► Subscribe► Subscribe METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,278,961

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,888,364Pyridyl inhibitors of hedgehog signalling► Subscribe
9,321,761Pyridyl inhibitors of hedgehog signalling► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,278,961

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2016203958► Subscribe
BrazilPI0514841► Subscribe
Canada2579002► Subscribe
China101072755► Subscribe
China102964294► Subscribe
Cyprus1112630► Subscribe
Denmark1789390► Subscribe
Eurasian Patent Organization200700538► Subscribe
Eurasian Patent Organization017262► Subscribe
Eurasian Patent Organization201100604► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Citi
McKesson
US Department of Justice
Colorcon
Argus Health
Chubb
Baxter
Deloitte
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot